Drawing for CVS SPECIALTY

USPTO serial 86913505

CVS SPECIALTY

Reviewed by CopyMark Law Group

Reg. 5324613Status 702Renewal
Filing date
Status date
Registration date
Oct 31, 2017
Examiner
MCBRIDE, THEODORE M
Law office
TMEG LAW OFFICE 103

What this means

This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.

Status 702: Status 702 means the registration is active, Section 8 was accepted, and a Section 15 declaration of incontestability was also accepted. Incontestability strengthens your rights by limiting certain challenges after five years of continuous use.

Need help with CVS SPECIALTY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
035Medical referrals; managed care services, namely, electronic processing of health care and pharmaceutical information; procurement, namely, purchasing pharmaceuticals for others; supplying prescription drugs to health plan participants for the funding organizationsACTIVEAug 29, 2016
036Insurance claims administration for medical claims and pharmaceuticals; processing of insurance claims and payment dataACTIVEMar 15, 2017
041Medical educational services, namely, providing courses of instruction in the medical fields of parenteral and enteral therapy and intraperitoneal therapy and treatment; medical education services namely, training for medical professionals and patients regarding the use and application of enteral and parenteral therapy for medical purposes and distributing course materials in connection therewith; medical educational services, namely, providing individualized and group instruction, seminars and workshops for patients and caregivers of patients requiring parenteral and enteral therapy for medical purposesACTIVEDec 31, 2016
044Medical services, namely, providing therapy management services relating to the provision of in-home and ambulatory infusion therapies and nutritional services; Medical services, namely, infusion services provided at home and in clinics; nursing services; providing medical information concerning hemophilia; Providing in-home and ambulatory dispensing and administering of infusion pharmaceuticals, and providing hemophilia, anti-infectives, pain remediation, palliative care, cardiac, inotropic, antitrypsin deficiency, pre-transplant, post-transplant, growth hormone, hepatitis, osteoarthritis, steroid, immune deficiency, rheumatoid arthritis, multiple sclerosis, interferon, alcohol dependency, oncology, fertility, vaccine and nutritional therapy servicesACTIVEMar 15, 2016

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 9, 2024NA85NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
Apr 9, 2024C15AREGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Apr 8, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL
Oct 11, 2023E815TEAS SECTION 8 & 15 RECEIVED
Oct 31, 2022REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Oct 31, 2017R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 28, 2017SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Sep 27, 2017CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Sep 20, 2017SUPCSTATEMENT OF USE PROCESSING COMPLETE
Sep 14, 2017AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL
Aug 28, 2017IUAFUSE AMENDMENT FILED
Aug 28, 2017EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Jul 1, 2017EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 29, 2017EX2GSOU EXTENSION 2 GRANTED
Jun 29, 2017EXT2SOU EXTENSION 2 FILED
Jun 29, 2017EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 22, 2016EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 20, 2016EX1GSOU EXTENSION 1 GRANTED
Dec 20, 2016EXT1SOU EXTENSION 1 FILED
Dec 20, 2016EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 5, 2016NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 10, 2016NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 10, 2016PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 20, 2016NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 16, 2016CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Mar 9, 2016DOCKASSIGNED TO EXAMINER
Feb 26, 2016MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED
Feb 25, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 23, 2016NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance